Industry: Immune suppressant drugs

MyBregs is an early-stage biopharmaceutical company exploring a new class of immune suppressant drugs that could be used to treat autoimmune and inflammatory disorders.
The company has developed a method for manufacturing induced B-regulatory cells, dubbed iBregs. These iBregs have been shown to cure autoimmune-related brain inflammation in mice.
MyBregs is aiming to turn these therapeutic B-cells into a successful immunotherapy for chronic autoimmune and inflammatory disorders.
Immunosuppressant drugs based on iBregs could also prove valuable for uses such as organ transplants. 

Back to companies

191 Peachtree Street, NE, Suite 849  |  Atlanta, Georgia 30303  |  404.332.9770  |  Directions  |  Privacy  |  GRA Venture Fund, LLC
Copyright © Georgia Research Alliance  |  All Rights Reserved